Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1050-1052

  Verma, Rahul Kumar ^a   Germishuizen, Willem A ^a,b   Motheo, M Portia ^a   Agrawal, Atul Kumar ^b   Singh, Amit Kumar ^c   Mohan, Mradul ^d   Gupta, Pushpa ^d,e   Gupta, Umesh Datta ^a   Cholo, Moloko ^a   Anderson, Ronald ^a   Fourie, P Bernard ^a   Misra, Amit ^a,b,c  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Deltamune (Pty) Ltd   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^e UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL CULTURE; COLONY FORMING UNIT; IN VITRO STUDY; INTRACELLULAR KILLING; MACROPHAGE; MONOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUBERCULAR AGENTS; CELLS, CULTURED; CLOFAZIMINE; DRUG DELIVERY SYSTEMS; LUNG; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84872859798     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01897-12     Document Type: Article

References (11)

1. Reddy VM, O'Sullivan JF, Gangadharam PR. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623.
2. Reddy V, Nadadhur MG, Daneluzzi D, O'Sullivan JF, Gangadharam PR. 1996. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40:633-636.
3. Feng PC, Fenselau CC, Jacobson RR. 1981. Metabolism of clofazimine in leprosy patients. Drug Metab. Dispos. 9:521-524.
4. Global Alliance for Drug Development TB. 2008. Handbook of antituberculosis agents. Tuberculosis 88:85-170.
5. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO, Geneva, Switzerland.
6. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. 2012. Clofazimine: Current status and future prospects. J. Antimicrob. Chemother. 67:290-298.
7. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51: 2830-2836.
8. Mathur A, Venkatesan K, Sreevatsa Kannan KB, Desikan KV. 1997. Effect of dietary fat on tissue disposition of clofazimine in mice receiving the drug orally as suspension in oils. Indian J. Pharmacol. 29:262-265.
9. RxList. 2008. Lamprene (clofazimine) soft gelatin capsules.WebMDLLC, Atlanta, GA. http://www.rxlist.com/lamprene-drug.htm.
10. Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R, Misra A. 2008. A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur. J. Pharm. Sci. 34:56-65.
11. Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P. 2012. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int. J. Tuberc. Lung Dis. 16:1119-1125.